Contents

I. Innovation: Key to Success in the Pharmaceutical Industry......1
   The Productivity Paradox .................................................................1
   The Blockbuster Imperative ..............................................................4
   High Risks in Drug Development ...................................................10
   Strategies for Growth .....................................................................12
   Differentiation via Clinical Profiles .................................................15
   Entering the Market Quickly .........................................................16
   Conclusions ..................................................................................17

II. The Industry Challenge: Do You Really Want to Be in This
    Business? ....................................................................................19
    High Complexity of the Industry .....................................................19
    How Attractive is the Pharmaceutical Industry? .............................22
    Force 1: Bargaining Power of Suppliers .........................................24
    Force 2: Bargaining Power of Buyers .............................................25
    Force 3: Risk of Entry from Potential Competitors ...........................26
    Force 4: Threat of Substitute Products ..........................................27
    Force 5: Rivalry among Established Companies ...............................28
    Force 6: The Regulators ................................................................28
    Conclusions ..................................................................................30

III. The Science and Technology Challenge: How to Find New
    Drugs ............................................................................................33
    Rise of the Biotechnology Industry: Boosting Innovation ............33
    High-Throughput Screening: Fail Earlier, Succeed Sooner .............38
    Combinatorial Chemistry: Cut Experimental Cycle Times .........39
    Bioinformatics: More than 100 Gigabytes of Data per Day ..........40
    Proteomics: Profiting from the Human Genome Project .............42
    Genomics: Towards Individualization and Mass Customization ....43
    Pharmacogenomics: Create Tailor-made Drugs .........................45
    Molecular Design: From Experimenting to Analytic Design ..........47
    Conclusions ..................................................................................48
IV. The Pipeline Management Challenge: How to Organize Innovation .......................................................................................................................... 51

The Relevance of Pipeline Management .............................................. 51
Complexity and Phases of the R&D Process ........................................... 56
The Importance of Project and Portfolio Management ......................... 65
The Disaggregation of the Pharmaceutical Value Chain ....................... 68
Impact of Outsourcing on Pharmaceutical R&D ................................. 71
Rising Importance of R&D Collaborations ........................................... 75
Research Alliances: Accessing Early-stage Innovation ......................... 78
In-licensing: Enhancing the Innovation Pipeline ................................... 81
Co-development: Mutually Benefiting from Joint Resources ................. 83
Out-licensing: Commercializing Internal Research Results .................. 86
How to Commercialize a Breakthrough Technology ......................... 95
Conclusions .......................................................................................... 100

V. The Internationalization Challenge: Where to Get Access to Innovation .................................................................................................................... 103

Trends and Drivers of R&D Internationalization .................................. 103
Primary Locations of Pharmaceutical R&D around the World ............. 108
New Opportunities for Drug Development in China ............................ 111
Three Principal Problems of Dispersed R&D ...................................... 117
Conclusions .......................................................................................... 121

VI. Management Answers to Pharmaceutical R&D Challenges ... 123

Managing R&D Organization at Roche .............................................. 123
Managing R&D Strategy at Schering ................................................... 125
Managing the Research-to-Development Handover at Roche ............. 127
Managing Outsourcing Activities at Solvias ...................................... 130
Managing Intellectual Property Rights at Bayer ................................ 133
Managing Out-licensing at Novartis ................................................... 137
Managing Uncertainty at Roche ......................................................... 144
Managing Global R&D at Major Swiss Pharma Companies ................ 145
Managing a Niche-Market Strategy at Intarcia .................................... 151
Managing Virtual Project Management Pools at Roche ..................... 153
Conclusions .......................................................................................... 156

VII. Future Directions and Trends .......................................................... 159
Bibliography ................................................................. 165
Index ................................................................. 173
Glossary ............................................................. 179
Authors ............................................................. 185
Leading Pharmaceutical Innovation
Trends and Drivers for Growth in the Pharmaceutical Industry
Gassmann, O.; Reepmeyer, G.; von Zedtwitz, M.
2008, XVI, 186 p. 47 illus., Hardcover
ISBN: 978-3-540-77635-2